This transaction
The acquisitionThe voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
Manufacture and sale of active pharmaceutical ingredients (APIs), intermediates and fine chemical products using phosgene as the principal raw material.
The impact of this transaction on the Company's consolidated results is currently under review. The Company will promptly disclose any matter requiring disclosure in the future.
| Item | Details |
|---|---|
| Transaction name | The acquisition |
| Counterparty name | VanDeMark Chemical, B.V. |
| Name of the Subject Company | Framochem Francia-Magyar Finomkemiai Kft |
| Business Description of the Subject Company | Manufacture and sale of active pharmaceutical ingredients (APIs), intermediates and fine chemical products using phosgene as the principal raw material. |
| Location of the Subject Company | Szerviz utca 5, 3700 Kazincbarcika, Hungary |
| Capital Stock of the Subject Company | HUF 700 million (¥332 million) |
| Date of Establishment of the Subject Company | 29 September 1992 |
| Net Sales of the Subject Company | HUF 18,915 million (fiscal year ended December 2024, ¥8,966 million) |
| Operating Profit of the Subject Company | HUF 4,102 million (fiscal year ended December 2024, ¥1,944 million) |
| Net Income of the Subject Company | HUF 3,854 million (fiscal year ended December 2024, ¥1,827 million) |
| Net Assets of the Subject Company | HUF 11,156 million (fiscal year ended December 2024, ¥5,288 million) |
| Acquisition price | Equity interests: €87 million (¥16,008 million, approximate amount) |
| Expenses other than the acquisition price | Advisory fees and other expenses: ¥600 million |
| Number of shares acquired | All equity interests (100%); number of voting rights: Not disclosed |
| Voting rights ownership percentage | Before 0％ → after 100％ |
| Impact on Business Performance | The impact of this transaction on the Company's consolidated results is currently under review. The Company will promptly disclose any matter requiring disclosure in the future. |
| Date of board resolution | 27 March 2026 |
| Contract Date | 27 March 2026 |
| Execution Date / Effective Date | Second quarter of the fiscal year ending March 2027 (scheduled) |
| Conditions Precedent to Execution | Satisfaction of the conditions stipulated in the agreement |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The acquisition is intended to strengthen and expand the specialty chemicals business set out in the next medium-term management plan and achieve non-linear growth. The Company expects to strengthen its global supply network and its position as a global niche leader by incorporating Framochem's technological capabilities and customer base and establishing direct manufacturing operations in regions of demand, including Europe.